PE20120421A1 - Composicion farmaceutica que comprende aleglitazar - Google Patents
Composicion farmaceutica que comprende aleglitazarInfo
- Publication number
- PE20120421A1 PE20120421A1 PE2011001309A PE2011001309A PE20120421A1 PE 20120421 A1 PE20120421 A1 PE 20120421A1 PE 2011001309 A PE2011001309 A PE 2011001309A PE 2011001309 A PE2011001309 A PE 2011001309A PE 20120421 A1 PE20120421 A1 PE 20120421A1
- Authority
- PE
- Peru
- Prior art keywords
- pharmaceutical composition
- composition obtained
- composition
- happiness
- includes happiness
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
SE REFIERE A UN PROCESO QUE COMPRENDE: A) PULVERIZAR UNA SOLUCION ACUOSA TAMPONADA CON TAMPON FOSFATO QUE CONTIENE 0.01 MG A 0.9 MG DE ALEGLITAZAR, UN AGLUTINANTE TAL COMO 0.1- 20MG DE POVIDONA Y UN TENSOACTIVO TAL COMO 0.1-2 MG DE LAURILSULFATO SOBRE UN DILUYENTE TAL COMO AZUCAR, CELULOSA MICROCRISTALINA, LACTOSA O ALMIDON Y UN DESINTEGRANTE TAL COMO 0.5-20 MG DE CROSCARMELOSA SODICA; B) MEZCLAR LA COMPOSICION OBTENIDA EN EL PASO (A) CON UN LUBRICANTE TAL COMO 0.5-3MG DE ESTEARATO DE MAGNESIO; C) COMPRIMIR LA COMPOSICION OBTENIDA EN EL PASO (B) PARA LA OBTENCION DE UNA TABLETA. DICHA COMPOSICION ES UTIL PARA EL TRATAMIENTO O PROFILAXIS DE LA DIABETES TIPO II O DE ENFERMEDADES CARDIOVASCULARES
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09151254 | 2009-01-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20120421A1 true PE20120421A1 (es) | 2012-05-04 |
Family
ID=42112184
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016000386A PE20160746A1 (es) | 2009-01-23 | 2010-01-13 | Composicion farmaceutica que comprende aleglitazar |
| PE2011001309A PE20120421A1 (es) | 2009-01-23 | 2010-01-13 | Composicion farmaceutica que comprende aleglitazar |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016000386A PE20160746A1 (es) | 2009-01-23 | 2010-01-13 | Composicion farmaceutica que comprende aleglitazar |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20100190835A1 (es) |
| EP (1) | EP2389166B1 (es) |
| JP (1) | JP5619027B2 (es) |
| KR (2) | KR20140002812A (es) |
| CN (1) | CN102292074B (es) |
| AR (1) | AR075041A1 (es) |
| AU (1) | AU2010206249B2 (es) |
| BR (1) | BRPI1007237B1 (es) |
| CA (1) | CA2748896C (es) |
| CL (1) | CL2011001777A1 (es) |
| CY (1) | CY1113641T1 (es) |
| DK (1) | DK2389166T3 (es) |
| ES (1) | ES2397558T3 (es) |
| HR (1) | HRP20130108T1 (es) |
| IL (1) | IL213671A (es) |
| MX (1) | MX2011007381A (es) |
| PE (2) | PE20160746A1 (es) |
| PL (1) | PL2389166T3 (es) |
| PT (1) | PT2389166E (es) |
| RU (1) | RU2537224C2 (es) |
| SG (1) | SG173058A1 (es) |
| SI (1) | SI2389166T1 (es) |
| TW (1) | TWI406861B (es) |
| WO (1) | WO2010084066A1 (es) |
| ZA (1) | ZA201104670B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013181384A1 (en) | 2012-05-31 | 2013-12-05 | Ratiopharm Gmbh | Solid state forms of aleglitazar sodium |
| WO2014016369A1 (en) | 2012-07-27 | 2014-01-30 | Ratiopharm Gmbh | Pharmaceutical formulation comprising aleglitazar and complexing agent |
| WO2014016370A1 (en) * | 2012-07-27 | 2014-01-30 | Ratiopharm Gmbh | Amorphous aleglitazar |
| WO2014016371A1 (en) | 2012-07-27 | 2014-01-30 | Ratiopharm Gmbh | Micronized aleglitazar |
| KR20150054829A (ko) * | 2012-09-12 | 2015-05-20 | 에프. 호프만-라 로슈 아게 | (S)-2-메톡시-3-｛4-[2-(5-메틸-2-페닐-옥사졸-4-일)-에톡시]-벤조[b]티오펜-7-일｝-프로피온산 및 이의 염의 고체 형태 |
| KR102569636B1 (ko) * | 2016-08-10 | 2023-08-23 | 에프. 호프만-라 로슈 아게 | Akt 단백질 키나아제 저해제를 포함하는 약학 조성물 |
| CN114404375B (zh) * | 2022-01-21 | 2023-06-27 | 武汉九珑人福药业有限责任公司 | 一种叶酸固体制剂及其原料组合物、制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2772615B1 (fr) * | 1997-12-23 | 2002-06-14 | Lipha | Comprime multicouche pour la liberation instantanee puis prolongee de substances actives |
| PL208074B1 (pl) * | 2001-05-15 | 2011-03-31 | Hoffmann La Roche | Pochodne oksazolu, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie pochodnych oksazolu |
| GB0303600D0 (en) * | 2003-02-17 | 2003-03-19 | Glaxo Group Ltd | Novel therapeutic method and compositions |
| US7262303B2 (en) * | 2003-09-29 | 2007-08-28 | Hoffman-La Roche Inc. | Process for the production of chiral propionic acid derivatives |
| US20060051413A1 (en) * | 2004-09-08 | 2006-03-09 | Chow Sing S M | Method of enhancing absorptions of transmucosal administration formulations |
| RU2007129642A (ru) * | 2005-02-25 | 2009-03-27 | Ф.Хоффманн-Ля Рош Аг (Ch) | Таблетки с улучшенным распределением лекарственного вещества |
| US20060270722A1 (en) * | 2005-05-31 | 2006-11-30 | Thornberry Nancy A | Combination of a dipeptidyl peptidase-IV inhibitor and a dual PPAR agonist for the treatment of diabetes and obesity |
| FR2894477A1 (fr) * | 2005-12-13 | 2007-06-15 | Galderma Res & Dev | Utilisation du naveglitazar pour la preparation d'une composition pharmaceutique destinee au traitement des affections dermatologiques |
| US20100210692A1 (en) * | 2007-03-28 | 2010-08-19 | Farmer Stephen R | Methods of treatment using sirt modulators and compositions containing sirt1 modulators |
-
2010
- 2010-01-13 WO PCT/EP2010/050343 patent/WO2010084066A1/en active Application Filing
- 2010-01-13 MX MX2011007381A patent/MX2011007381A/es active IP Right Grant
- 2010-01-13 SG SG2011052305A patent/SG173058A1/en unknown
- 2010-01-13 ES ES10701340T patent/ES2397558T3/es active Active
- 2010-01-13 JP JP2011546748A patent/JP5619027B2/ja not_active Expired - Fee Related
- 2010-01-13 BR BRPI1007237-3A patent/BRPI1007237B1/pt not_active IP Right Cessation
- 2010-01-13 DK DK10701340.1T patent/DK2389166T3/da active
- 2010-01-13 CA CA2748896A patent/CA2748896C/en not_active Expired - Fee Related
- 2010-01-13 KR KR1020137032602A patent/KR20140002812A/ko not_active Ceased
- 2010-01-13 PT PT107013401T patent/PT2389166E/pt unknown
- 2010-01-13 PE PE2016000386A patent/PE20160746A1/es unknown
- 2010-01-13 RU RU2011134964/15A patent/RU2537224C2/ru not_active IP Right Cessation
- 2010-01-13 KR KR1020117016128A patent/KR20110105798A/ko not_active Ceased
- 2010-01-13 PL PL10701340T patent/PL2389166T3/pl unknown
- 2010-01-13 CN CN2010800050015A patent/CN102292074B/zh not_active Expired - Fee Related
- 2010-01-13 SI SI201030129T patent/SI2389166T1/sl unknown
- 2010-01-13 AU AU2010206249A patent/AU2010206249B2/en not_active Ceased
- 2010-01-13 PE PE2011001309A patent/PE20120421A1/es not_active Application Discontinuation
- 2010-01-13 EP EP10701340A patent/EP2389166B1/en not_active Not-in-force
- 2010-01-19 US US12/689,296 patent/US20100190835A1/en not_active Abandoned
- 2010-01-21 AR ARP100100131A patent/AR075041A1/es not_active Application Discontinuation
- 2010-01-22 TW TW099101817A patent/TWI406861B/zh not_active IP Right Cessation
-
2011
- 2011-06-20 IL IL213671A patent/IL213671A/en unknown
- 2011-06-23 ZA ZA2011/04670A patent/ZA201104670B/en unknown
- 2011-07-22 CL CL2011001777A patent/CL2011001777A1/es unknown
-
2012
- 2012-11-12 US US13/674,310 patent/US20130072529A1/en not_active Abandoned
- 2012-12-03 CY CY20121101181T patent/CY1113641T1/el unknown
-
2013
- 2013-02-07 HR HRP20130108AT patent/HRP20130108T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120421A1 (es) | Composicion farmaceutica que comprende aleglitazar | |
| ES2524771T3 (es) | Composiciones farmacéuticas que comprenden levetiracetam y procedimientos para su preparación | |
| PE20070698A1 (es) | Comprimido de disgregacion rapida intraoral que contiene hidrocloruro de ambroxol | |
| HN2011001446A (es) | Compuesto utiles para inhibir chk1 | |
| ECSP10010160A (es) | Composiciones farmaceuticas de accion doble basadas en super-estructuras de antagonista/bloqueador del receptor de angiotensina (arb) e inhibidor de endopeptidasa neutra (nep) | |
| CL2008003827A1 (es) | Composicion para tabletas de desintegracion oral que comprende al menos una droga ( temazepam), 0,5-3% de un polimero aglutinanete para odt, un alcohol de azucar y/o sacarido, y un desintegrante; metodo para prepararla; util para tratar una enfermedad o condicion como un trastorno del sueño en pacientes con disfagia.. | |
| PE20061345A1 (es) | Composicion farmaceutica que comprende sorafenib | |
| PE20090015A1 (es) | Preparacion solida | |
| CL2012000793A1 (es) | Composicion farmaceutica que comprende 1-cloro-4-(3-d-glucopiranos-il)-2-[4-((s)-tetrahidrofuran-3-iloxi)-bencil]benceno, clorhidrato de metformina y uno o mas excipientes farmaceuticos. | |
| BRPI0922796A2 (pt) | Comprimido farmacêutico para administração por via oral e método de fabricação do mesmo | |
| IN2015DN02907A (es) | ||
| DOP2011000047A (es) | Agentes terapeuticos 414 | |
| CR10992A (es) | Preparacion solida que comprende alogliptina y pioglitazona | |
| RU2014138035A (ru) | Твердая фармацевтическая композиция, содержащая 1-(3-(2-(1-бензотиофен-5-ил)этокси)пропил)азетидин-3-ол или его соль | |
| PE20220751A1 (es) | Composiciones solidas que comprenden un agonista del glp-1, un inhibidor del sglt2 y una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico | |
| PE20080376A1 (es) | Formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina derivado de fluorofenilpiridina | |
| BR112012027794A2 (pt) | tablete entérico | |
| MX387086B (es) | Preparacion compuesta, que contiene derivado novedoso de acido 3-(4-(benciloxi)fenil)hex-4-inoico y otro ingrediente activo, para prevenir o tratar enfermedades metabolicas | |
| CR11398A (es) | Compuesto inhibidor de glicogeno fosforilasa y composicion farmaceutica del mismo. | |
| CL2011002650A1 (es) | Composicion que comprende n-(4-(2-furil)-5-(tetrahidropiran-4-ilcarbonil)tiazol-2-il)-2-metilpiridin-5-carboxamida y l-dopa; uso del compuesto para el tratamiento de un trastorno del movimiento secundario de la terapia con l-dopa; uso del compuesto y l-dopa y/o para el tratamiento y/o profilaxis de la enfermedad de parkinson. | |
| RU2008135718A (ru) | Композиции клопидогреля бисульфата | |
| ES2721649T3 (es) | Comprimidos de N-acetilcisteína tragables | |
| PE20061390A1 (es) | Formulaciones de acido hidroxamico suberoilanilida y procedimientos para la produccion de las mismas | |
| PE20060768A1 (es) | Composicion farmaceutica que comprende hidroclorotiazida y telmisartano | |
| BRPI0713371A2 (pt) | método para a produção de um produto medicamentoso contendo olmesartan medoxomil, e, produto medicamentoso contendo olmesartan medoxomil |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |